ICLR vs. MRK: ICON vs. Merck Stock Comparison
How do ICON (ICLR) and Merck (MRK) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
ICON (ICLR) and Merck (MRK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while MRK is classified in Pharmaceuticals.
| Profile Item | ICLR | MRK |
|---|---|---|
| Name | ICON plc | Merck & Co., Inc. |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 15.34 billion USD | 361.73 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 15, 1998 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ICLR | MRK |
|---|---|---|
| Total Return (1Y) | 30.55% | 76.14% |
| Total Return (3Y, Annualized) | -6.05% | 16.48% |
| Total Return (5Y, Annualized) | -5.40% | 15.77% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Merck (MRK) is heavily traded at around 10.24M shares per day, whereas ICON (ICLR) sees a more moderate 943.50K — larger orders in the latter may require more patience and tighter control over order sizing.
| Metric | ICLR | MRK |
|---|---|---|
| Volatility (1Y, Annualized) | 68.62% | 30.24% |
| Beta (5Y) | 1.17 | 0.11 |
| Max Drawdown (5Y) | -76.87% | -43.44% |
| Avg. Volume (3M) | 943.50K | 10.24M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ICLR | MRK |
|---|---|---|
| Sharpe Ratio (1Y) | 0.38 | 2.38 |
| Sortino Ratio (1Y) | 0.52 | 4.33 |
Profitability
ROE (TTM)
Both ICON (ICLR) at 4.70% and Merck (MRK) at 5.06% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.06%
- Max
- 109.18%
- Q3
- 6.23%
- MRK
- 5.06%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
ICON (ICLR) at 5.26% retains a top-quartile share of revenue as profit, ahead of Merck (MRK) at 3.64%, which keeps about the industry-typical share.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.64%
- Max
- 18.05%
- Q3
- 4.78%
- MRK
- 3.64%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Merck (MRK) at 35.22% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.22%
- Max
- 83.12%
- MRK
- 35.22%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ICLR | MRK |
|---|---|---|
| ROE (TTM) | 4.70% | 5.06% |
| ROA (TTM) | 0.85% | 11.29% |
| Net Margin (TTM) | 5.26% | 3.64% |
| Operating Margin (TTM) | 10.73% | 35.22% |
| Gross Margin (TTM) | 23.44% | 75.20% |
Growth
Revenue Growth
Both ICON (ICLR) at 0.76% and Merck (MRK) at 1.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Merck (MRK) at 8.01% is around its peer norm for EPS growth, while ICON (ICLR) at -71.56% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | ICLR | MRK |
|---|---|---|
| Revenue Growth (YoY) | 0.76% | 1.31% |
| Revenue Growth (3Y CAGR) | 2.15% | 3.12% |
| EPS Growth (YoY) | -71.56% | 8.01% |
| EPS Growth (3Y CAGR) | -23.82% | 8.43% |
Financial Strength
Current Ratio (MRQ)
Both ICON (ICLR) at 1.32 and Merck (MRK) at 1.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRK
- 1.35
- Min
- 0.10
Debt / Equity (MRQ)
ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while Merck (MRK) at 1.20 uses more debt funding than most peers.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.20
- Max
- 1.42
- MRK
- 1.20
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ICLR | MRK |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 1.35 |
| Debt / Equity (MRQ) | 0.38 | 1.20 |
| Net Debt / EBITDA | 5.55 | 1.50 |
Dividends
Dividend Yield (TTM)
ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Merck (MRK) reports a yield of 2.29%, ranking against industry peers normally.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.29%
- MRK
- 2.29%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Merck (MRK) reports payout ratio above 100% at 343.43%, meaning dividends exceeded current-period earnings; ICON (ICLR) pays no dividend (payout 0.00%).
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
343.43%
- MRK
- 343.43%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ICLR | MRK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.29% |
| Dividend Payout Ratio (TTM) | 0.00% | 343.43% |
Valuation
P/E Ratio (TTM)
Both look expensive on trailing earnings: ICON (ICLR) at 81.90 sits in the richer P/E ratio quartile, and Merck (MRK) at 148.21 is richer still, above its industry range.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
148.21
- MRK
- 148.21
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Merck (MRK) at 5.37 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.37
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MRK
- 5.37
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
ICON (ICLR) at 1.68 looks cheap against book in the lower P/B ratio quartile, while Merck (MRK) at 8.06 carries a premium in the upper quartile — a clear price-to-book gap.
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.06
- Max
- 13.53
- MRK
- 8.06
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ICLR | MRK |
|---|---|---|
| P/E Ratio (TTM) | 81.90 | 148.21 |
| P/S Ratio (TTM) | 1.86 | 5.37 |
| P/B Ratio (MRQ) | 1.68 | 8.06 |
| Free Cash Flow Yield (TTM) | 3.51% | 3.88% |